Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Howard Chang, Staci Williamson, Daniel Chandra, Andy Chen, Rachel Cook, Amrita Desai, Arpita Gandhi, Brandon Hayes-Lattin, Curtis Lachowiez, Jessica Leonard, Richard Maziarz, Laura Newell, Jennifer Saultz, Ronan Swords, Elie Traer, Gabrielle Meyers

Blood (2025) 146 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2025-6085

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai, Arpita Gandhi, Jennifer Saultz, Gabrielle Meyers, Laura Newell, Rachel Cook, Elie Traer, Curtis Lachowiez, Ronan Swords, Richard Maziarz, Theodore Braun, Brandon Hayes-Lattin, Jessica Leonard

Blood (2025) 146 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2025-3372

Published: 2025

Journal Articles

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Blood (2025) 146 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2025-3354

Published: 2025

Journal Articles

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Blood (2025) 146 (Supplement 1): 654.

https://doi.org/10.1182/blood-2025-654

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Blood (2025) 146 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2025-4252

Published: 2025

Journal Articles

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Blood (2025) 146 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2025-7744

Published: 2025

Journal Articles

Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation.

Aditi Chatterjee, Moaath Mustafa Ali, Christopher Bailey, Yuchen Liu, Donald Small, Catherine Smith, Elie Traer, Yin Wang, Giovannino Silvestri, Maria Baer

Blood (2025) 146 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2025-3288

Published: 2025

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Andrew M. Brunner, Amer M. Zeidan, Elie Traer, Yazan F. Madanat, Janelle Meyer, Harry Erba, Praneeth Baratam, Uma Borate, Yuri Sano, Aram Oganesian, Lixia Zhu, Harold N. Keer, Michael R. Savona

Blood (2024) 144 (Supplement 1): 662.

https://doi.org/10.1182/blood-2024-203569

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2024-203361

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2024-208505

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation.

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only